ViaLase

ViaLase, Inc. is a clinical-stage medical technology company based in Aliso Viejo, California. It is focused on disrupting the conventional glaucoma treatment paradigm with the introduction of a truly noninvasive image-guided femtosecond laser treatment called femtosecond laser image-guided high-precision trabeculotomy (FLigHT). The ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver the FLigHT treatment.

The FLigHT procedure involves creating microscopic drainage channels in the trabecular meshwork, allowing excess fluid to leave the eye and reducing intraocular pressure (IOP). This approach aims to provide a noninvasive, nonsurgical option for glaucoma patients, addressing an unmet need for those who may not be ready for cataract surgery or have already undergone it but are struggling with medical therapy.

ViaLase has completed enrollment in a pivotal VIA-002 trial, a prospective, randomized, controlled, multi-center study comparing the ViaLase Laser to selective laser trabeculoplasty (SLT) in adult patients with primary open-angle glaucoma (POAG). The primary effectiveness endpoint is a reduction in mean unmedicated IOP from baseline to six and 12 months. ViaLase has also presented 36-month data from its first-in-human study, demonstrating the safety and IOP-lowering efficacy of the FLigHT treatment as of April 2024.

The company's leadership team has extensive experience in developing, designing, manufacturing, and commercializing the first femtosecond lasers for ophthalmic surgery for refractive and cataract patients. ViaLase is backed by venture capital firms, including Venture Investors Health Fund, Arboretum Ventures, and Falcon Vision, an ophthalmology investment platform supported by KKR.